VF
TXG icon

Virtu Financial’s 10x Genomics TXG Stock Holding History

Virtu Financial’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,523
Closed -$567K – 2257
2025
Q3 		$567K Buy
+48,523
New +$633K 0.03% 508
2023
Q4 		– Sell
-9,773
Closed -$403K – 2015
2023
Q3 		$403K Buy
+9,773
New +$508K 0.04% 404
2023
Q1 		– Sell
-22,815
Closed -$831K – 2115
2022
Q4 		$831K Buy
+22,815
New +$746K 0.11% 167
2021
Q4 		– Sell
-9,982
Closed -$1.45M – 2186
2021
Q3 		$1.45M Sell
9,982
-1,490
-13% -$256K 0.13% 145
2021
Q2 		$2.25M Buy
+11,472
New +$2.08M 0.22% 62
2020
Q4 		– Sell
-2,173
Closed -$271K – 1807
2020
Q3 		$271K Buy
+2,173
New +$228K 0.05% 480

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's TXG Position: Q4 2025 in Review

Virtu Financial sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 48,523 shares — an estimated $567K sold.

Virtu Financial first reported a position in TXG in Q3 2020 and held it in 6 quarters. The position peaked at $2.25M in Q2 2021. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Virtu Financial reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Virtu Financial sold 48,523 10x Genomics shares in Q4 2025, an estimated $567K.
  • Virtu Financial first reported a position in 10x Genomics in Q3 2020 and held it in 6 quarters.
  • Virtu Financial's 10x Genomics position peaked at $2.25M in Q2 2021.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.